



# Agenda

- ❑ How can Life Sciences companies effectively manage “Consent”? *The perspective from the Clinical research and patients stand point*
- ❑ What is the impact of data privacy on the transparency landscape  
*Switch to legitimate interest, HCP data*
- ❑ What is the current enforcement environment  
*Lessons learned from the Google/CNIL case*